B

uffeted by problems with its all-important diabetes franchise, Sanofi (SNY) is bidding $11.6 billion for Bioverativ (BIVV) — a hemophilia company spun off by Biogen (BIIB) — hoping it will help solve its strategic and financial woes.

But skepticism abounds.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.